Paz-Ares, Luis

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., Garcia-Gomez, R., Massuti, B., Sánchez, J. M., Porta, R., et al. (2015) · JAMA Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 239

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Reck, M., Ciuleanu, T.-E., Dols, M. C., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 153

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Szczesna, A., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 133

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 130

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Segal, N. H., Melero, I., Moreno, V., Steeghs, N., Marabelle, A., Rohrberg, K., Rodriguez-Ruiz, M. E., Eder, J. P., Eng, C., Manji, G. A., et al. (2024) · Nature Communications

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 80

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.

Ramalingam, S. S., Ciuleanu, T. E., Pluzanski, A., Lee, J.-S., Schenker, M., Bernabe Caro, R., Lee, K. H., Zurawski, B., Audigier-Valette, C., Provencio, M., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 67

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Ahn, M.-J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., et al. (2025) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 66

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 65

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H., et al. (2020) · Frontiers in Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 52

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Carbone, D. P., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Felip, E., Cheng, Y., Juan-Vidal, O., et al. (2025) · ESMO Open

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 43

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Reuss, J. E., Gandhi, S. G., Spigel, D. R., Janne, P. A., Paz-Ares, L. G., Gadgeel, S. M., Patel, J. D., Passiglia, F., Spira, A. I., Edelman, M. J., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 7

A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.

Pujol, J.-L., Vansteenkiste, J. F., Paz-Ares, L. G., Gregorc, V., Mazieres, J., Awad, M. M., Janne, P. A., Chisamore, M. J., Hossain, A., Chen, Y., et al. (2020) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 7

Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).

Reinmuth, N., Garassino, M. C., Juan-Vidal, O., Girard, N., Haggstrom, D. E., Cobo, M., Hochmair, M., Summers, Y. J., Hendriks, L., Kato, T., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 2